Tirzepatide
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Eli Lilly · Phase 1/2 · Active, not recruiting · Enrollment 190
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part 1: ARO-INHBE | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 1: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 2: ARO-INHBE + Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 3: Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 3: ARO-INHBE + Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Part 3: Placebo + Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |